Lake Street Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $41

Benzinga Newsdesk www.benzinga.com Positive 50.4%

Neg 0% Neu 0% Pos 50.4%

Lake Street analyst Daniel Brims initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating and announces Price Target of $41.